Ennov, a provider of end-to-end regulatory, quality, and clinical software solutions for life sciences and healthcare organizations, announced a strategic growth investment led by Bregal Sagemount with participation from Ardian. The investment will support Ennov’s expansion plans, including accelerating AI innovation, scaling its product offering, and expanding its global go-to-market operations.
Founded and headquartered in Paris, Ennov provides a unified compliance platform designed to serve as a centralized system of record for life sciences organizations worldwide. Its platform supports key operational domains including Regulatory, Quality, Commercial, Clinical, and Pharmacovigilance, while enabling AI-driven efficiency, improved compliance consistency, and faster deployment through an integrated architecture and unified data model.
Developed over more than 25 years, Ennov’s software is designed to replace fragmented legacy systems and point solutions, helping organizations manage complex regulatory requirements across global authorities including the FDA and EMA within a single platform. The company currently serves approximately 650 customers and more than 500,000 users across 30 countries.
The company said the investment reflects growing demand for integrated and AI-enabled software solutions in the life sciences industry as regulatory and quality workflows become increasingly complex.
As part of the transaction, Gene Yoon, Curt Witte, and Harrison Brunelli from Bregal Sagemount, along with Alexis Saada from Ardian, will join Ennov’s board of directors.
The transaction is expected to close in late Q2 2026, subject to regulatory approvals and customary closing conditions.
KEY QUOTES:
“We were looking for partners who understand the complexity of our customers’ environments and the opportunity ahead for integrated and AI-enabled software in life sciences. Sagemount and Ardian bring that perspective, and we look forward to continuing to build innovative solutions that support our customers’ most critical processes.”
Olivier Pâris, Founder And CEO, Ennov
“Regulatory and quality workflows in life sciences are becoming increasingly complex, while the cost of managing them across disconnected systems continues to rise. Olivier and his team have spent more than two decades building a mission-critical solution that enables customers to not only manage but optimize their processes to achieve better business outcomes. We believe this opportunity is only accelerating with Ennov’s new AI products, and we’re excited to support the Company in its next phase of growth.”
Gene Yoon, Managing Partner, Bregal Sagemount
“Ennov represents exactly the kind of technology company we seek to support at Ardian Growth. We are excited to join forces with Bregal Sagemount, bringing together two leading US and European investment firms behind an exceptional management team. With its strong international footprint and rapidly expanding AI capabilities, Ennov is uniquely positioned to shape the future of regulatory, quality, and clinical software in life sciences worldwide.”
Alexis Saada, Head Of Growth, Ardian
